Journal of Shandong University (Health Sciences) ›› 2022, Vol. 60 ›› Issue (10): 42-48.doi: 10.6040/j.issn.1671-7554.0.2022.0091
Previous Articles Next Articles
SHI Xiaohan1, LI Huayu1, LI Feng2
CLC Number:
[1] Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma[J]. N Engl J Med, 2005, 352(10): 987-996. [2] Ostrom QT, Cioffi G, Gittleman H, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016[J]. Neuro Oncol, 2019, 21(Suppl 5): v1-v100. [3] Ostrom QT, Kinnersley B, Armstrong G, et al. Age-specific genome-wide association study in glioblastoma identifies increased proportion of ‘lower grade glioma’-like features associated with younger age[J]. Int J Cancer, 2018, 143(10): 2359-2366. [4] 欧阳辉, 穆林森, 鲁明. 积极治疗老年胶质瘤[C] //第十五届中国医师协会神经外科医师年会摘要集. 深圳: 中国医师协会神经外科医师分会, 2020: 732. [5] Glaser SM, Dohopolski MJ, Balasubramani GK, et al. Glioblastoma multiforme(GBM)in the elderly: initial treatment strategy and overall survival[J]. J Neurooncol, 2017, 134(1): 107-118. [6] Alvarez DES, Alvarez-Vega MA, Balbin M, et al. Prognostic factors and survival study in high-grade glioma in the elderly[J]. Br J Neurosurg, 2016, 30(3): 330-336. [7] Han Q, Liang H, Cheng P, et al. Subtotal resection on survival outcomes in elderly patients with high-grade glioma: a systematic review and meta-analysis[J]. Front Oncol, 2020, 10: 151. doi: 10.3389/fonc.2020.00151. [8] Barbagallo G, Altieri R, Garozzo M, et al. High grade glioma treatment in elderly people: is it different than in younger patients? analysis of surgical management guided by an intraoperative multimodal approach and its impact on clinical outcome[J]. Front Oncol, 2020, 10: 631255. doi: 10.3389/fonc.2020.631255. [9] Young JS, Chmura SJ, Wainwright DA, et al. Management of glioblastoma in elderly patients[J]. J Neurol Sci, 2017, 380: 250-255. doi: 10.1016/j.jns.2017.07.048. [10] Pirkkalainen JM, Jaaskelainen AS, Halonen P. Retrospective single-center study on elderly patients with glioblastoma between 2014 and 2018 evaluating the effect of age and performance status on survival[J]. Neurooncol Pract, 2022, 9(2): 142-148. [11] Youland RS, Schomas DA, Brown PD, et al. Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience[J]. J Neurooncol, 2017, 133(2): 339-346. [12] Laigle-Donadey F, Greffard S. Management of glioblastomas in the elderly population[J]. Rev Neurol(Paris), 2020, 176(9): 724-732. [13] Ene CI, Cimino PJ, Fine HA, et al. Incorporating genomic signatures into surgical and medical decision-making for elderly glioblastoma patients[J]. Neurosurg Focus, 2020, 49(4): E11. doi: 10.3171/2020.7. FOCUS 20418. [14] Fu C, Li Z, Mao Z. Association between social activities and cognitive function among the elderly in china: a cross-sectional study[J]. Int J Environ Res Public Health, 2018, 15(2): 231. [15] Brown PD, Chung C, Liu DD, et al. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma[J]. Neuro Oncol, 2021, 23(8): 1337-1347. [16] Johnson DR, Sawyer AM, Meyers CA, et al. Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma[J]. Neuro Oncol, 2012, 14(6): 808-816. [17] Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary[J]. Neuro Oncol, 2021, 23(8): 1231-1251. [18] Wick W, Weller M, van den Bent M, et al. MGMT testing-the challenges for biomarker-based glioma treatment[J]. Nat Rev Neurol, 2014, 10(7): 372-385. [19] Pirozzi CJ, Yan H. The implications of IDH mutations for cancer development and therapy[J]. Nat Rev Clin Oncol, 2021, 18(10): 645-661. [20] Zhao F, Zhang J, Li P, et al. Prognostic value of Ki-67 index in adult medulloblastoma after accounting for molecular subgroup: a retrospective clinical and molecular analysis[J]. J Neurooncol, 2018, 139(2): 333-340. [21] Kawasoe T, Takeshima H, Yamashita S, et al. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme[J]. J Neurosurg, 2015, 122(2): 317-323. [22] Wang Q, Hu B, Hu X, et al. Tumor evolution of glioma-intrinsic gene expression subtypes associates with immunological changes in the microenvironment[J]. Cancer Cell, 2018, 33(1): 152. [23] 李培栋, 王新军, 单峤, 等. 脑胶质瘤细胞MGMT甲基化状态与细胞对烷化剂耐药性的关系[J]. 中国老年学杂志, 2015, 35(16): 4463-4464. [24] Kim BS, Kong DS, Seol HJ, et al. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma[J]. J Neurooncol, 2017, 133(3): 615-622. [25] Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors[J]. N Engl J Med, 2015, 372(26): 2499-2508. [26] Louis DN, Giannini C, Capper D, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant[J]. Acta Neuropathol, 2018, 135(4): 639-642. [27] Ceccarelli M, Barthel FP, Malta TM, et al. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma[J]. Cell, 2016, 164(3): 550-563. [28] Luo Y, Zhang X, Mo M, et al. High Ki-67 immunohistochemical reactivity correlates with poor prognosis in bladder carcinoma: a comprehensive meta-analysis with 13,053 patients involved[J]. Medicine(Baltimore), 2016, 95(15): e3337. doi: 10.1097/MD.0000000000003337. [29] Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients[J]. Breast Cancer Res Treat, 2015, 153(3): 477-491. [30] Johannessen AL, Torp SH. The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas[J]. Pathol Oncol Res, 2006, 12(3): 143-147. [31] Preusser M, Hoeftberger R, Woehrer A, et al. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours-a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group[J]. Histopathology, 2012, 60(6): 885-894. |
[1] | ZHENG Su, CHEN Shuhua, LI Hua, DENG Jie, CHEN Chunhong, WANG Xiaohui, FENG Weixing, HAN Xiaodi, ZHANG Yujia, LI Na, LI Mo, FANG Fang. Correlation between EEG variations and BASED evaluation of the efficacy of ACTH treatment in 54 cases of infantile spasms [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 91-96. |
[2] | WANG Lihui, GAO Min, KONG Beihua. Angiosarcoma of the uterus: a report of 2 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 108-112. |
[3] | HE Shiqing, LI Wanwan, DONG Shuqing, MOU Jingyi, LIU Yuying, WEI Siyu, LIU Zhao, ZHANG Jiaxin. Construction of a prognostic risk model of pyroptosis-related genes in breast cancer based on database [J]. Journal of Shandong University (Health Sciences), 2022, 60(8): 34-43. |
[4] | ZHANG Yufeng, XU Min, XING Xiuli, PANG Shuguang, HU Keqing. Epidemiological characteristics of 689 patients with non-ST-segment elevation myocardial infarction [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 118-122. |
[5] | WU Richao, LIU Hong, WANG Ze, GAO Shanshan, LI Xiufang, SHI Yuhua. Pregnancy outcomes of in vitro fertilization-intracytoplasmic sperm injection-embryo transfer in women 40 years and above [J]. Journal of Shandong University (Health Sciences), 2022, 60(6): 35-39. |
[6] | DONG Xiaoqian, LI Guanjiang, XU Qianqian, XU Hongwei. Comparison among ERCP combined with ursodeoxycholic acid and other therapies in the treatment of choledocholithiasis complicated with cholecystolithiasis [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 59-66. |
[7] | LI Linlin, WANG Kai. Prediction of hepatocellular carcinoma prognostic genes based on bioinformatics [J]. Journal of Shandong University (Health Sciences), 2022, 60(5): 50-58. |
[8] | ZHAO Sibo, PENG Li, LING Hongxiang. Relationship between medical insurance participation and risk of suicide among rural elderly [J]. Journal of Shandong University (Health Sciences), 2022, 60(4): 113-118. |
[9] | SUN Zhenguo, TIAN Hui. Optimization of the procedures in minimally invasive esophagectomy: the Qilu practices [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 33-37. |
[10] | ZHU Yongcun, ZHAO Xiushi, SUN Nannan, YAO Zhigang, ZHOU Xingchen, MU Kun. Prostate clear cell adenocarcinomas: a report of 3 cases and literature review [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 102-107. |
[11] | YU Shujuan, WANG Meijuan, CHEN Li, CAO Yingjuan LYU Xiaoyan, LIU Xueyan, LIN Peng, YAN Jingzheng. Influencing factors of mild cognitive impairment in elderly patients with type 2 diabetes [J]. Journal of Shandong University (Health Sciences), 2022, 60(11): 108-112. |
[12] | CHEN Liyu, XIAO Juan, LYU Xianzhong, DUAN Baomin, HONG Fanzhen. Risk factors influencing prognosis of lower extremity deep vein thrombosis in pregnant and parturient women [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 38-42. |
[13] | TIAN Yaotian, WANG Bao, LI Yeqin, WANG Teng, TIAN Liwen, HAN Bo, WANG Cuiyan. Machine learning models based on interpretive CMR parameters can predict the prognosis of pediatric myocarditis [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 43-49. |
[14] | WANG Xin, GUO Dan, LIANG Jiarui, GUO Li, WANG Jian. Impact of social capital on health promotion behaviors of the elderly [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 97-103. |
[15] | LI Wanwan, ZHOU Wenkai, DONG Shuqing, HE Shiqing, LIU Zhao, ZHANG Jiaxin, LIU Bin. Construct of a risk assessment model of breast cancer immune-related lncRNAs based on the database information [J]. Journal of Shandong University (Health Sciences), 2021, 59(7): 74-84. |
|